M&A·IB

[VC's Pick] Big Money Flows into Smart 'Medical AI and Robotics' Technologies That Replace Human Hands

Soyoung Park
2026-11-21 10:04:03
[Edaily Marketin, Reporter Soyoung Park ] This week (November 16–20), startups in various fields—including robotics, image analysis, and business platforms—secured investments from venture capital (VC) firms and accelerators (ACs). In particular, investors focused their attention on companies that combine medical technology with cutting-edge technologies such as artificial intelligence (AI) and robotics. Building on their solid technological capabilities, which have been recognized by investors, these companies plan to expand into the global market.

(Photo: Getty Images)


Medical robotics startup “Mediintech”
Mediintech, developer of an AI-powered robotic endoscope, successfully raised 33.8 billion won in a Series C funding round. The round was jointly led by existing investor Atinum Investment and new investor KB Investment. Existing investors, including Smilegate Investment, SL Investment, ICF (Nextrans), and Wooshin Venture Investment, also participated. Additionally, K2 Investment Partners joined as a new investor.

Investors noted that MediInTech’s technological competitiveness and growth potential are likely to be highly valued during its future initial public offering (IPO) process. They also believed the company’s technology could revolutionize the flexible endoscopic surgical robot market. As a result, the company is expected to emerge as a global medical AI surgical robot firm.

Mediintech plans to conclude its Series C round by securing additional funding within the year. The company intends to use the funds from this investment to expand its product portfolio and develop next-generation surgical robots. Previously, the company secured Series A funding of 8 billion won in 2022 and Series B funding of 20 billion won in 2024. Including this latest investment, the company’s cumulative funding to date totals approximately 62.2 billion won.

MediInTech was founded in 2020. The company has been developing AI-powered robotic endoscopes that combine robotic precision control technology with AI. Its flagship product is the “INTION S,” which utilizes motor-based precision control technology. The company has expanded the scope of AI application from image analysis to controlling the actual movements of medical devices.

'Sumbit AI,' Developer of Medical Image Interpretation Solutions
Sumbit AI, which develops generative AI-based
medical image interpretation
solutions, has secured a total of 15 billion won in funding. The company recently finalized a Series A investment round worth approximately 12 billion won, led by SV Investment. Altos Ventures, Kiwoom Investment, and iM Investment Partners also participated. In addition, the company was selected for the Ministry of SMEs and Startups’ “Scale-Up TIPS” specialized program. It will receive linked support for research and development funding totaling up to 3 billion won over three years. As a result, the company’s cumulative investment and funding amount has reached approximately 20 billion won.

Sumbit AI was founded in July 2024 by a team from Kakao Brain that had developed an AI-powered chest X-ray interpretation assistance solution. CEO Bae Woong, who previously served as Chief Healthcare Officer (CHO) at Kakao Brain, co-founded the company with former Kakao Brain colleagues. The company develops vision-language models (VLMs) capable of understanding medical images and creates products that can be used in actual clinical settings. Previously, radiologists wrote their reports on a blank screen. The company aims to change this process so that radiologists review and revise preliminary reports generated by AI.

With this funding, Sumbit AI plans to expand its product lineup beyond chest X-rays to include complex 3D multi-sequence imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI). “AIRead-CT,” currently under development, is a CT preliminary report solution covering the brain, chest, abdomen, and pelvis. The company aims to launch the product in 2027. This solution will be unveiled for the first time at the Radiological Society of North America (RSNA) 2026 exhibition, taking place from the 29th to December 2 at McCormick Place in Chicago. Building on this, the company plans to accelerate its pursuit of global regulatory approvals—including U.S. FDA and European CE certification—and commercialization.

"Manifest," Operator of a Planning Workspace
Manifest, an operator of an AI-based planning workspace, has secured investment from Silicon Valley-based AC Alchemist and the University of Chicago. This investment came after the company was selected for the "Alchemist 2027" startup incubation program. The company overcame a competition ratio of approximately 40 to 1. The Polsky Center, the University of Chicago’s hub for entrepreneurship and technology commercialization, also participated as a co-investor.

Manifest will participate in a six-month on-site program starting with a founder retreat and U.S. market entry program to be held in San Francisco next January. The company will receive mentoring from dedicated partners and sales coaches, as well as support for securing investment. Following this, it will present at a Demo Day in front of U.S. investors.

Manifest Solution is delivered as software-as-a-service (SaaS). When users input ideas or meeting notes, the platform generates draft software development plans, including △ a requirements definition document (PRD) △ a functional specification △ user flows △ and wireframes. Users can integrate the solution with AI tools such as Claude Code and Cursor to put it to immediate use.

Economy

Corporation

IT·Science

Economy

[VC's Pick] Big Money Flows into Smart 'Medical AI and Robotics' Technologies That Replace Human Hands

This week (November 16–20), startups in various fields—including robotics, image analysis, and business platforms—secured investments from venture capital (VC) firms and accelerators (ACs). In particu…
2026-11-21 10:04:03

Corporation

Celltrion Sees Full-Scale Results from Direct Sales in the U.S. … “Projected Operating Profit of 2.4 Trillion Won Next Year”

Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
2026-11-21 06:01:02

IT·Science

Penetrium Bioscience and AprilBio Rally as AriBio-Linked Stocks Diverge [K-Bio Pulse]

South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penet…
2026-11-21 08:17:02